I den 28- dages forsøgsperiode i det placebokontrollerede ADDRESS forsøg var hyppigheden af tilfælde af alvorlige blødning henholdsvis 51 (3, 9%) og 28 (2, 2%) af de drotrecogin alfa (aktiveret) - behandlede og placebobehandlede patienter (p=0, 01).
In the placebo-controlled ADDRESS study, the incidence of serious bleeding events during the 28-day study period was 51 (3.9%) and 28 (2.2%) in drotrecogin alfa (activated)-treated and placebo-treated patients, respectively (p=0.01).